The accelerating demand for highly potent active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates (ADCs) is compelling contract development and manufacturing…
Read More
Eli Lilly Acquires Ajax Therapeutics for Up to $2.3 Billion in Strategic Move to Bolster Oncology Pipeline
Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read More
Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases
Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…
Read More
AACR 2026 Annual Meeting in San Diego to Highlight Precision Oncology and Integrated Therapies Under Co-Chairs Alice Shaw and Paul Mischel
The global scientific community is counting down the days until the highly anticipated 2026 annual meeting of the American Association…
Read More
Regeneron Pharmaceuticals and Telix Pharmaceuticals Forge Strategic Alliance to Advance Precision Oncology Through Radiopharmaceutical Innovation
Regeneron Pharmaceuticals and Telix Pharmaceuticals have announced a significant partnership aimed at accelerating the development and commercialization of novel radiopharmaceutical…
Read More
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers – Pharmaceutical Technology
The landscape of oncology drug development is undergoing a profound transformation, increasingly centered on precision immunotherapies where biomarker-defined patient populations…
Read More
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline
Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…
Read More
The Rise of Antibody-Drug Conjugates: Precision Oncology’s Evolving Frontier
Antibody-drug conjugates (ADCs) represent a significant leap forward in targeted cancer therapy, a sophisticated class of drugs that marries the…
Read More
MSD’s $6.7 Billion Acquisition of Terns Pharmaceuticals Signals a Bold Strategic Pivot in Oncology to Secure Future Growth
On March 25, Merck & Co. (MSD) announced a significant strategic move, acquiring Terns Pharmaceuticals for an estimated $6.7 billion…
Read More
MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry
In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…
Read More
